Endometrial Cancer Market Research Report – Forecast to 2027

Global Endometrial Cancer Market Research Report, by Diagnosis (Pelvic Examination, Transvaginal Ultrasound, Endometrial Biopsy), Treatment (Hysterectomy, Radiation), End-User (Hospitals & Clinics, Ambulatory Surgical Centers) – Global Forecast Till 2027

ID: MRFR/MED/4765-HCR | February 2021 | Region: Global | 100 pages

Please note that the assessment period of report has been updated from 2018-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Scenario


The abnormal growth of endometrium cells in the uterus is termed as endometrial cancer which is also known as uterine cancer. Endometrial cancer is diagnosed at an early stage as women experience abnormal vaginal bleeding. It is reported that endometrial cancer is the sixth most common cancer in women all over the world. The endometrial cancer market is expected to witness a tremendous growth owing to the rising prevalence of endometrial cancer. Other key factors such as the growing obesity among women, increase in menopausal hormone therapy, change in sedentary lifestyle, socioeconomic factors, growing consumption of unhealthy diet, increasing occurrence of Polycystic Ovarian Syndrome (PCOS), and increasing prevalence of breast or ovarian tumor are contributing towards the growth of the market.  Diabetes is another risk factor that leads to the development of endometrial cancer. According to the American Cancer Society,  endometrial cancer is four times common in diabetic women than in normal women. Such factors contribute to endometrial cancer among women.


However, factors such as high cost of diagnostic procedures, expensive treatments, and side effects associated with hysterectomy procedures are expected to restrict the market growth during the forecast period.


Research Methodology


Market Research Future research is conducted by industry experts who offer insights into industry structure, market segmentation, assessment, Competitive Landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, the varying trends of segments and categories geographically presented are studied and are estimated based on the primary and secondary research.



  • Primary Research


Extensive primary research was conducted to gain a deeper insight into the market and the industry performance. In this particular report, we have conducted primary surveys (interviews) with key level executives (VPs, CEOs, Marketing Directors, Business Development Managers, and many more) of the major players who are active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed, over the next five to ten years.



  • Secondary Research


Secondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and commercial study of the global endometrial cancer market. It was also used to obtain key information about major players, market classification, and segmentation according to industry trends, geographical markets, and developments related to the market and perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, SEC filings, journals, white papers, corporate presentations, company websites, international organization of chemical manufacturers, some paid databases, and many others.


Segmentation


The global endometrial cancer market is segmented on the basis of diagnosis, treatment, and end-user. The endometrial cancer market, by diagnosis, is categorized into pelvic examination, transvaginal ultrasound, endometrial biopsy, dilation and curettage (D&C), and laparoscopy. On the basis of treatment, the market is segmented into hysterectomy techniques, radiation, hormone therapy, chemotherapy, and palliative care. The hysterectomy techniques category includes open abdominal hysterectomy, total vaginal hysterectomy, total laparoscopic hysterectomy, and robotic hysterectomy. The radiation category includes external radiation and internal radiation (brachytherapy). The hormonal therapy includes progestins, tamoxifen, luteinizing hormone-releasing hormone agonists, and aromatase inhibitors. The chemotherapy segment is categorized into paclitaxel, carboplatin, doxorubicin, and cisplatin. On the basis of end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, diagnostic centers, gynecology centers, feminist health centers, and others.     


On the basis of region, the global endometrial cancer market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.


Key players


Some of the key players in the global endometrial cancer market are Pfizer Inc., General Electric Company, Koninklijke Philips N.V., LUPIN, PHYTON, Bayer AG, Celgene Corporation, Johnson & Johnson, CooperSurgical Inc., LiNA Medical USA, Conceptus Inc., Hologic Inc., Karl Storz GmbH & Co. Kg, and Boston Scientific Corporation.


Regional Market Summary


The endometrial cancer market is dominated by North America owing to the rising prevalence of breast cancer. The US Breast Cancer Statistics projected 266,120 new cases of invasive breast cancer and 63,960 new cases of non-invasive breast cancer in 2018. Other factors such as increasing healthcare expenditure and increasing obesity within the female population drive the market growth in this region.


It is estimated that Europe stood second in the global endometrial cancer market owing to the increasing prevalence of ovarian cancer in this region. According to the Cancer Research UK in 2015, 7270 new cases of ovarian cancer were registered in the UK. Thus, the increasing prevalence of ovarian cancer in this region influences the growth of this market in this region.


Asia-Pacific was projected to be the fastest growing region for the global endometrial cancer market in 2017. The market is expected to witness growth owing to the rising prevalence of diabetes in women, changing lifestyle, and growing obesity within the female population. According to the American Diabetes Association, diabetes in South Asia is expected to rise by 150% from 2000 to 2035. This provides a favorable background for the market to grow.


The Middle East and Africa holds the least share in the global endometrial cancer market due to the presence of stringent government policies and poor economies. However, the market is expected to witness growth due to the rising healthcare expenditure, growing private sector in the healthcare domain, and insurance coverage in the Middle East.


Global Endometrial Cancer Market Share (%), by Region, 2017


 Endometrial Cancer Market Share
Sources: World Cancer Research Fund International, the American Cancer Society, Inc, Center for Disease Control and Prevention


Global Endometrial Cancer Market, by Diagnosis



  • Pelvic examination

  • Transvaginal ultrasound

  • Endometrial biopsy

  • Dilation and curettage (D&C)

  • Diagnostic laparoscopy


Global Endometrial Cancer Market, by Treatment



  • Hysterectomy Techniques

    • Open abdominal hysterectomy

    • Total vaginal hysterectomy

    • Total laparoscopic hysterectomy

    • Robotic hysterectomy



  • Radiation

    • External radiation

    • Internal radiation (brachytherapy)



  • Hormone therapy

    • Progestins

    • Tamoxifen

    • Luteinizing hormone-releasing hormone agonists

    • Aromatase inhibitors



  • Chemotherapy

    • Paclitaxel

    • Carboplatin

    • Doxorubicin

    • Cisplatin



  • Palliative care


Global Endometrial Cancer market, by End-User



  • Hospitals & Clinics

  • Ambulatory Surgical Centers

  • Diagnostic Centers

  • Gynecology Centers

  • Feminist Health Centers


Global Endometrial Cancer Market, by Region



  • The Americas

  • Europe

  • Asia-Pacific

  • The Middle East & Africa


Global Endometrial Cancer Market, by Key Players



  • Pfizer Inc.

  • General Electric Company

  • Koninklijke Philips N.V.

  • LUPIN, PHYTON

  • Bayer AG

  • Celgene Corporation

  • Johnson & Johnson

  • CooperSurgical Inc.

  • LiNA Medical USA

  • Conceptus Inc.

  • Hologic Inc.

  • Karl Storz GmbH & Co. Kg,

  • Boston Scientific Corporation


Intended Audience



  • Pharmaceutical companies

  • Biotechnological institutes

  • Government and private laboratories

  • Research and Development (R&D) companies

  • Medical research laboratories

  • Market research and consulting service providers



TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Endometrial Cancer Market, by Diagnosis

6.1 Introduction

6.2 Pelvic examination

6.3 Transvaginal ultrasound

6.4 Endometrial biopsy

6.5 Dilation and curettage (D&C)

6.6 Diagnostic laparoscopy

Chapter 7. Global Endometrial Cancer Market, by Treatment

7.1 Introduction

7.2 Hysterectomy Techniques

7.2.1 Open abdominal hysterectomy

7.2.2 Total vaginal hysterectomy

7.2.3 Total laparoscopic hysterectomy

7.2.4 Robotic hysterectomy

7.3 Radiation

7.3.1 External radiation

7.3.2 Internal radiation (brachytherapy)

7.4 Hormone therapy

7.4.1 Progestins

7.4.2 Tamoxifen

7.4.3 Luteinizing hormone-releasing hormone agonists

7.4.4 Aromatase inhibitors

7.5 Chemotherapy

7.5.1 Paclitaxel

7.5.2 Carboplatin

7.5.3 Doxorubicin

7.5.4 Cisplatin

7.6 Palliative care

Chapter 8. Global Endometrial Cancer market, by End-User

8.1 Introduction

8.2 Hospitals & Clinics

8.3 Ambulatory Surgical Centers

8.4 Diagnostic Centers

8.5 Gynecology Centers

8.6 Feminist health centers

Chapter 9. Global Endometrial Cancer Market, by Region

9.1 Introduction

9.2 America

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia-Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

Chapter 10. Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Pfizer Inc

11.1.1 Company Overview

11.1.2 Type Overview

11.1.3 Financials

11.2.4 Key Developments

11.1.5 SWOT Analysis

11.2 Koninklijke Philips N.V

11.2.1 Company Overview

11.2.2 Type Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Boston Scientific Corporation

11.3.1 Company Overview

11.3.2 Type Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 LUPIN

11.4.1 Company Overview

11.4.2 Type/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 PHYTON

11.5.1 Company Overview

11.5.2 Type Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 Bayer AG

11.6.1 Company Overview

11.6.2 Type Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 CELGENE CORPORATION.

11.7.1 Overview

11.7.2 Type Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Johnson & Johnson

11.8.1 Overview

11.8.2 Type Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 CooperSurgical Inc.

11.9.1 Overview

11.9.2 Type Overview

11.9.3 Financials

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.10 LiNA Medical USA

11.10.1 Overview

11.10.2 Type Overview

11.10.3 Financials

11.10.4 Key Developments

11.10.5 SWOT Analysis

11.11 CONCEPTUS INC

11.11.1 Overview

11.11.2 Type Overview

11.11.3 Financials

11.11.4 Key Developments

11.11.5 SWOT Analysis

11.12 Hologic Inc.,

11.12.1 Overview

11.12.2 Type Overview

11.12.3 Financials

11.12.4 Key Developments

11.12.5 SWOT Analysis

11.13 Karl Storz GmbH & Co. Kg

11.13.1 Overview

11.13.2 Type Overview

11.13.3 Financials

11.13.4 Key Developments

11.13.5 SWOT Analysis

11.14 GE Healthcare

11.14.1 Overview

11.14.2 Type Overview

11.14.3 Financials

11.14.4 Key Developments

11.14.5 SWOT Analysis

11.15 Others

Chapter 12 Appendix

LIST OF TABLES

Table 1 Endometrial Cancer Market Industry Synopsis, 2020-2027

Table 2 Global Endometrial Cancer Market Estimates & Forecast, 2020-2027, (USD Million)

Table 3 Global Endometrial Cancer Market, by Region, 2020-2027, (USD Million)

Table 4 Global Endometrial Cancer Market, by Diagnosis, 2020-2027, (USD Million)

Table 5 Global Endometrial Cancer Market, by Treatment, 2020-2027, (USD Million)

Table 6 Global Endometrial Cancer Market, by End-User, 2020-2027, (USD Million)

Table 7 North America Endometrial Cancer Market, by Diagnosis, 2020-2027, (USD Million)

Table 8 North America Endometrial Cancer Market, by Treatment, 2020-2027, (USD Million)

Table 9 North America Endometrial Cancer Market, by End-User, 2020-2027, (USD Million)

Table 10 US Endometrial Cancer Market, by Diagnosis, 2020-2027, (USD Million)

Table 11 US Endometrial Cancer Market, by Treatment, 2020-2027, (USD Million)

Table 12 US Endometrial Cancer Market, by End-User, 2020-2027, (USD Million)

Table 13 Canada Endometrial Cancer Market, by Diagnosis, 2020-2027, (USD Million)

Table 14 Canada Endometrial Cancer Market, by Treatment, 2020-2027, (USD Million)

Table 15 Canada Endometrial Cancer Market, by End-User, 2020-2027, (USD Million)

Table 16 South America Endometrial Cancer Market, by Diagnosis, 2020-2027, (USD Million)

Table 17 South America Endometrial Cancer Market, by Treatment, 2020-2027, (USD Million)

Table 18 South America Endometrial Cancer Market, by End-User, 2020-2027, (USD Million)

Table 19 Europe Endometrial Cancer Market, Diagnosis, 2020-2027, (USD Million)

Table 20 Europe Endometrial Cancer Market, by Treatment, 2020-2027, (USD Million)

Table 21 Europe Endometrial Cancer Market, by End-User, 2020-2027, (USD Million)

Table 22 Western Europe Endometrial Cancer Market, by Diagnosis, 2020-2027, (USD Million)

Table 23 Western Europe Endometrial Cancer Market, by Treatment, 2020-2027, (USD Million)

Table 24 Western Europe Endometrial Cancer Market, by End-User, 2020-2027, (USD Million)

Table 25 Eastern Europe Endometrial Cancer Market, by Diagnosis, 2020-2027, (USD Million)

Table26 Eastern Europe Endometrial Cancer Market, by Treatment, 2020-2027, (USD Million)

Table 27 Eastern Europe Endometrial Cancer Market, by End-User, 2020-2027, (USD Million)

Table 28 Asia-Pacific Endometrial Cancer Market, by Diagnosis, 2020-2027, (USD Million)

Table 29 Asia-Pacific Endometrial Cancer Market, by Treatment, 2020-2027, (USD Million)

Table 30 Asia-Pacific Endometrial Cancer Market, by End-User, 2020-2027, (USD Million)

Table 31 The Middle East & Africa Endometrial Cancer Market, by Diagnosis, 2020-2027, (USD Million)

Table 32 The Middle East & Africa Endometrial Cancer Market, by Treatment, 2020-2027, (USD Million)

Table 33 The Middle East & Africa Endometrial Cancer Market, by End-User, 2020-2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Endometrial Cancer Market

Figure 3 Market Dynamics for Global Endometrial Cancer Market

Figure 4 Global Endometrial Cancer Market Share, by Diagnosis 2020

Figure 5 Global Endometrial Cancer Market Share, by Treatment 2020

Figure 6 Global Endometrial Cancer Market Share, by End-User, 2020

Figure 7 Global Endometrial Cancer Market Share, by Region, 2020

Figure 8 North America Endometrial Cancer Market Share, by Country, 2020

Figure 9 Europe Endometrial Cancer Market Share, by Country, 2020

Figure 10 Asia-Pacific Endometrial Cancer Market Share, by Country, 2020

Figure 11 Middle East & Africa Endometrial Cancer Market Share, by Country, 2020

Figure 12 Global Endometrial Cancer Market: Company Share Analysis, 2020 (%)

Figure 13 PFIZER INC: Key Financials

Figure 14 PFIZER INC: Segmental Revenue

Figure 15 PFIZER INC: Geographical Revenue

Figure 16 Koninklijke Philips N.V: Key Financials

Figure 17 Koninklijke Philips N.V: Segmental Revenue

Figure 18 Koninklijke Philips N.V: Geographical Revenue

Figure 19 Boston Scientific Corporation: Key Financials

Figure 20 Boston Scientific Corporation: Segmental Revenue

Figure 21 Boston Scientific Corporation: Geographical Revenue

Figure 22 LUPIN: Key Financials

Figure 23 LUPIN: Segmental Revenue

Figure 24 LUPIN: Geographical Revenue

Figure 25 Bayer AG: Key Financials

Figure 26 Bayer AG: Segmental Revenue

Figure 27 Bayer AG: Geographical Revenue

Figure 28 PHYTON: Key Financials

Figure 29 PHYTON: Segmental Revenue

Figure 30 PHYTON: Geographical Revenue

Figure 31 CELGENE CORPORATION. : Key Financials

Figure 32 CELGENE CORPORATION. : Segmental Revenue

Figure 33 CELGENE CORPORATION. : Geographical Revenue

Figure 34 Johnson & Johnson: Key Financials

Figure 35 Johnson & Johnson: Segmental Revenue

Figure 36 Johnson & Johnson: Geographical Revenue

Figure 37 CooperSurgical Inc.: Key Financials

Figure 38 CooperSurgical Inc.: Segmental Revenue

Figure 39 CooperSurgical Inc.: Geographical Revenue

Figure 40 LiNA Medical USA: Key Financials

Figure 41 LiNA Medical USA: Segmental Revenue

Figure 42 LiNA Medical USA: Geographical Revenue

Figure 46 Hologic Inc.: Key Financials

Figure 47 Hologic Inc.: Segmental Revenue

Figure 48 Hologic Inc.: Geographical Revenue

Figure 49 Karl Storz GmbH & Co. Kg: Key Financials

Figure 50 Karl Storz GmbH & Co. Kg: Segmental Revenue

Figure 51 Karl Storz GmbH & Co. Kg: Geographical Revenue

Figure 52 C.R. Bard: Key Financials

Figure 53 C.R. Bard: Segmental Revenue

Figure 54 C.R. Bard: Geographical Revenue

Figure 55 GE Healthcare: Key Financials

Figure 56 GE Healthcare: Segmental Revenue

Figure 57 GE Healthcare: Geographical Revenue